Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Invested Capital (2016 - 2025)

Haemonetics has reported Invested Capital over the past 16 years, most recently at $2.1 billion for Q4 2025.

  • Quarterly results put Invested Capital at $2.1 billion for Q4 2025, up 77.28% from a year ago — trailing twelve months through Dec 2025 was $2.1 billion (up 77.28% YoY), and the annual figure for FY2025 was $2.0 billion, up 67.41%.
  • Invested Capital for Q4 2025 was $2.1 billion at Haemonetics, up from $2.1 billion in the prior quarter.
  • Over the last five years, Invested Capital for HAE hit a ceiling of $2.1 billion in Q4 2025 and a floor of $770.4 million in Q3 2022.
  • Median Invested Capital over the past 5 years was $1.2 billion (2023), compared with a mean of $1.3 billion.
  • Biggest five-year swings in Invested Capital: crashed 33.97% in 2023 and later skyrocketed 135.73% in 2025.
  • Haemonetics' Invested Capital stood at $991.6 million in 2021, then grew by 6.13% to $1.1 billion in 2022, then soared by 36.57% to $1.4 billion in 2023, then fell by 16.17% to $1.2 billion in 2024, then surged by 77.28% to $2.1 billion in 2025.
  • The last three reported values for Invested Capital were $2.1 billion (Q4 2025), $2.1 billion (Q3 2025), and $2.1 billion (Q2 2025) per Business Quant data.